Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Canaccord analyst John Newman lowered the firm’s price target on Regeneron (REGN) to $150 from $170 and keeps a Hold rating on the shares. The firm said its target decrease is driven by more ...

Regeneron reported Q4 2024 EPS of $12.07, beating consensus estimates by 71 cents. Revenues rose 10.3% YoY to $3.79 billion, beating $3.74 billion consensus analyst estimates. Non-GAAP net income ...

We subsequently announced a clinical trial supply agreement with Regeneron for Libtayo in combination with IMM-1-104 in patients with non-small cell lung cancer and aim to get these new trials up ...